New $350 million life sciences fund debuts
Boston-based Cure Ventures is focused on early-stage investments in life science and biotechnology, primarily on those start-ups developing new therapeutics.
There’s a new life sciences venture fund that has announced its inaugural closure at $350 million.
Boston-based Cure Ventures is focused on early-stage investments in life science and biotechnology, primarily on those start-ups developing new therapeutics. According to this news release, the firm was founded in 2021 “by a network of highly accomplished industry veterans” that include Managing Partners Richard (Rich) Lim, David (Dave) Fallace, and Lou Tartaglia. The trio has played major roles in the success of several biotechnology companies including Juno Therapeutics, Agios Therapeutics, Nuvation Bio, and many others.
Cure’s investment thesis is founded on three tenets:
- A seed funding model that allows Cure to de-risk the science and set companies up for success;
- Genetic validation that increases the probability of success; and
- Embedded Cure operators to drive the best day-to-day decision making in collaboration with founders.
Regarding the first point, it was noted in the announcement that Cure’s seed funding model allows for important de-risking activities – a critical step in the early drug development process. That sets companies up for success in the clinic and beyond. As part of this process, Cure intends to follow through and co-lead subsequent Series A and B rounds of promising companies, seeing such companies through to their exits.
